AYTU BioPharma

AYTU

Market cap $20.9M

DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL. Management will be presenting on Wednesday, December 3rd at 10:30 a.m.

Aytu BioPharma, Inc. ( AYTU ) Q1 2026 Earnings Call November 13, 2025 4:30 PM EST Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Greetings.

Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.

Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balance at September 30, 2025 Company remains on track to launch EXXUA ™ (gepirone) extended-release tablets ("EXXUA " ) in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / November 13, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 first quarter.

DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m.

DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2, 2030 under 35 U.S.C.

AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.

DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences: 2025 Maxim Growth Summit Date: October 22, 2025 Location: New York City Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com to schedule one-on-one meetings with Aytu's management. Planet MicroCap Showcase: TORONTO 2025 Date: October 22, 2025 - October 23, 2025 Location: Toronto Presentation Time: 2:30 p.m.

DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences: MicroCap Rodeo Fall Conference Date: Thursday, September 25, 2025 Location: New York City Presentation Time: 2:00 p.m. Eastern time Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024 Lytham Partners Fall 2025 Investor Conference Date: Tuesday, September 30, 2025 Location: Virtual Presentation Time: 2:45 p.m.

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2025 Earnings Call September 23, 2025 4:30 PM EDT Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Greetings.